TY - JOUR
T1 - Outcomes in chronic lymphocytic leukemia patients on novel agents in the US Veterans Health Administration System
AU - Frei, Christopher R.
AU - Le, Hannah
AU - McHugh, Daniel
AU - Ryan, Kellie
AU - Jones, Xavier
AU - Galley, Samantha
AU - Franklin, Kathleen
AU - Baus, Courtney J.
AU - Tavera, Juan
AU - Janania-Martinez, Michelle
AU - Gregorio, David
AU - Ananth, Snegha
AU - Uribe, Ricardo
AU - Surapaneni, Prathibha
AU - Espinoza-Gutarra, Manuel
AU - Song, Michael M.
AU - Teng, Chengwen
AU - Obodozie-Ofoegbu, Obiageri O.
AU - Nooruddin, Zohra
N1 - Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205 CLL patients who initiated treatment with a novel oral agent. For 1L ibrutinib, 33% (n = 107) discontinued therapy during the study, of which 64% discontinued due to adverse events (AEs). For relapsed/refractory (R/R) ibrutinib, 35% (n = 262) discontinued therapy, of which 63% discontinued due to AEs. For R/R venetoclax, 31% (n = 27) discontinued therapy, of which 41% were due to AEs. For idelalisib, 84% (n = 41) discontinued therapy, of which 54% were due to AEs. This real-world study suggests that AEs play an important role in dose reductions and discontinuations; however, physician inexperience in using these drugs when they were first introduced could be part of what is leading to these negative outcomes.
AB - The US veteran population has a high proportion of chronic lymphocytic leukemia (CLL) risk factors. Using the Veterans Health Administration (VHA) population, we conducted a retrospective chart review of 1205 CLL patients who initiated treatment with a novel oral agent. For 1L ibrutinib, 33% (n = 107) discontinued therapy during the study, of which 64% discontinued due to adverse events (AEs). For relapsed/refractory (R/R) ibrutinib, 35% (n = 262) discontinued therapy, of which 63% discontinued due to AEs. For R/R venetoclax, 31% (n = 27) discontinued therapy, of which 41% were due to AEs. For idelalisib, 84% (n = 41) discontinued therapy, of which 54% were due to AEs. This real-world study suggests that AEs play an important role in dose reductions and discontinuations; however, physician inexperience in using these drugs when they were first introduced could be part of what is leading to these negative outcomes.
KW - Chronic lymphocytic leukemia
KW - adverse events
KW - chart review
KW - discontinuation
KW - dose reduction
KW - novel agents
UR - http://www.scopus.com/inward/record.url?scp=85100842857&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100842857&partnerID=8YFLogxK
U2 - 10.1080/10428194.2021.1876863
DO - 10.1080/10428194.2021.1876863
M3 - Article
C2 - 33569992
AN - SCOPUS:85100842857
SN - 1042-8194
VL - 62
SP - 1664
EP - 1673
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 7
ER -